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ABSTRACT
Abnormal telomere maintenance has been significantly implicated in tumor
development and progression. Telomere length has recently emerged as a promising
predictor for the risk of various cancers including hepatocellular carcinoma (HCC).
Nonetheless, the vast majority of these studies measured telomere length in
hepatocytes and one in peripheral blood lymphocytes with conflicting results. Moreover,
no studies have been reported on using circulating DNA telomere length as a noninvasive biomarker of HCC risk. In this nested case-control study, we used real-time
quantitative PCR to determine the relative telomere length (RTL) in serum DNA samples
from 140 hepatitis B virus (HBV)-related HCC (HBV-HCC) cases and 280 frequencymatched cancer-free HBV controls. We found that HBV-HCC cases had a significantly
longer RTL (median, 0.31; range, 0.02-2.31) versus HBV controls (median, 0.20; range,
0.01-1.60) (P=0.003). Using the median RTL value in controls as the cutoff point,
individuals with longer RTLs exhibited a significantly increased risk of HCC compared to
those with short RTLs in an univariate logistic regression analysis (odds ratio [OR]=1.55,
95% confidence interval [CI] 1.02-2.33, P=0.038). However, the strength of this
association attenuated after multivariate adjustment (OR=1.40, 95% CI 0.90-2.19,
P=0.132). In a quartile analysis, a significant dose-response relationship was noted in
the univariate analysis (P trend=0.017) which was attenuated in the multivariate analysis
(P trend=0.079). Further analyses revealed that the significant association between serum
RTL and HCC risk was only evident in non-cirrhotic (OR=3.54, 95% CI 1.58-7.93
P=0.002), but not in cirrhotic (OR=0.95, 95% CI 0.55-1.64, P=0.860) HBV patients.
Moreover, the significantly increased HCC risk conferred by cirrhosis seemed to be
modulated by RTL with a significant interaction effect (P for interaction=0.013).
Collectively, our data suggested that RTL in circulating cell-free serum DNA could
potentially be used as a novel non-invasive biomarker for non-cirrhotic HCC. Prospective
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cohort studies are warranted to further validate this finding and assess its clinical
significance in HCC prevention.
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INTRODUCTION
In the United States, the incidence of new acute HBV infection decreased in the
past two decades, but the number of patients living with chronic HBV infection has been
growing significantly. This development is partly due to the trend of increasing
immigration from areas with high HBV endemicity such as Asian and Sub-Arab countries
[1]. Among the more than 40 million Americans born outside of the United States, about
1.5 million have chronic HBV infection. Moreover, over 60% of current HBV patients in
the United States are relatively young and as these patients age, significant increases in
HBV-induced hepatocellular carcinoma (HCC) and corresponding medical costs are
expected to occur [1]. Thus, continuous monitoring of these patients and identification of
high-risk individuals for more targeted and intensive intervention are important to the
reduction of HBV-induced burden.
Telomeres consist of small tandem nucleotide repeats (TTAGGG in humans) that
form the physical ends of eukaryotic chromosomes [2]. The main function of telomeres is
to stabilize the linear chromosome ends and protect them from degradation and other
insults resulting from DNA damage response as well as end-to-end fusion [3, 4]. Due to
the end replication inefficiency of DNA polymerase, telomeres shorten by 50 to 200 base
pairs within each cell division cycle in normal somatic cells [5]. When the shortening of
telomeres reaches a critical point, loss of telomere protection will lead to replicative
senescence and/or apoptosis in normal cells, which in turn prevents tumor initiation
caused by genomic instability [6, 7]. In addition to the end replication issue, other factors
such as oxidative stress, chronic inflammation, and loss of telomere binding proteins
may also contribute to telomere shortening and lead to the tumorigenesis of many solid
cancers including HCC [8-10]. Furthermore, several studies have demonstrated a
significant correlation between decreased telomere length of tissue DNAs and promotion
of hepatocarcinogenesis [11-14].
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Recently, Liu et al. conducted a case-control study in a Chinese population and
reported that longer telomeres in peripheral blood leukocytes (PBLs) conferred an
increased risk of HCC [15]. This finding was consistent with several epidemiologic
reports indicating a positive correlation between longer telomere length in blood cells
and a greater susceptibility to breast cancer [16], melanoma [17], and non-Hodgkin
lymphoma [18], whereas contradictory to the findings of other studies demonstrating that
shorter telomeres were associated with increased risk in various cancers [19]. In HCC,
mounting evidence has substantiated the correlation between short telomere length in
liver tissues and increased cancer risk [20]. These paradox findings regarding telomere
length in cancer predisposition suggest that the previously observed associations might
be tissue and/or tumor specific, which warrants further evaluation.
Biomarkers based on circulating cell-free serum or plasma samples have unique
advantages over other specimens due to their non-invasive nature, especially in
prospective studies that have been followed-up for extended time periods but only
collected serum or plasma samples at the time of study initiation. Circulating serum DNA
as non-invasive predictive, diagnostic, and prognostic biomarkers has been extensively
investigated in many cancers [21-23]. In the current study, we sought to evaluate the
association between serum DNA telomere length and the risk of HBV-related HCC
(HBV-HCC) using a nested case-control approach in a clinic-based cohort of Korean
HBV patient population.

MATERIALS AND METHODS
Study population
The subjects in this study were selected from an existing and ongoing clinicbased cohort. The patients were consecutively enrolled from those who visited the Liver
Disease Prevention Center at Thomas Jefferson University Hospital for treatment of liver
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diseases, such as chronic HBV or HCV infection, fibrosis, cirrhosis, or HCC. There were
no restrictions on age, sex, ethnicity, and disease etiology in patient enrollment.
Enrollment started from 1988 and is still ongoing. As of October 2010, the cohort
included more than 2600 patients, of which 90% were of Korean ancestry. More than
90% of the patients in this cohort had HBV infection. To minimize confounding effects
from disease etiology and ethnicity, we restricted the current study to Korean HBV
patients. This study has been approved by the Institutional Review Board of Thomas
Jefferson University.
Epidemiologic and clinical data collection
Demographic and clinical data were obtained for each patient through medical
chart review and consulting with the treating physicians. Demographic variables
collected in this research included age, sex, ethnicity, smoking status, drinking status,
cirrhosis, and family history of cancer. An individual who smoked more than 100
cigarettes in lifetime was defined as an ever smoker, otherwise as a never smoker.
Never drinkers were defined as those who never consumed alcohol or consumed less
than or equal to one drink per month. Ever drinkers were those who consumed more
than one drink per month. Liver cirrhosis and HCC were determined by the combined
use of clinical diagnosis and imaging studies (ultrasound, computed tomography, or
magnetic resonance imaging). Blood sample was drawn for each participant for clinical
laboratory test, and the remaining serum sample was stored at -80 ºC for research
purpose.
Measurement of relative telomere length
Circulating cell-free serum DNA was extracted from 200 µL serum sample using
QIAamp DNA Blood Mini kit (Qiagen, CA) according to the manufacturer’s protocol. The
relative telomere length (RTL) of each DNA sample was determined by quantitative realtime polymerase chain reaction (qRT-PCR) using a protocol described by Cawthon [24],
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which measured the ratio of the copy number of telomere repeats to the copy number of
a human single copy gene, 36B4, with minor modifications. Briefly, the PCR reaction
(10 µL) for the telomere or 36B4 amplification consisted of 1 X SYBR Green Master Mix
(Applied Biosystems), 200 nmol/L each telomere or 36B4 specific primers, and 2 µL
purified serum DNA sample. The thermal cycling conditions for both telomere and 36B4
were 95 ºC for 10 min followed by 40 cycles of 95 ºC for 15 seconds and 58 ºC for 1 min
with signal collection. The primer sequences were as follows: forward telomere primer
(Tel-1), 5’-CGGTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT-3’; reverse
telomere primer (Tel-2), 5’-GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT3’; forward human 36B4 primer, 5’-CAGCAAGTGGGAAGGTGTAATCC-3’; reverse
human 36B4 primer, 5’-CCCATTCTATCATCAACGGGTACAA-3’. All samples were
assayed in duplicate on a 0.1 mL fast plate using a StepOnePlus real-time PCR system
(Applied Biosystems, CA). The same negative controls and calibrator DNAs were
included on each plate for quality control and calibration of PCR efficiency. A reference
DNA sample was used to construct a standard curve for RTL measurement on each
plate. The reference DNA was extracted from 5 ml pooled serum from 25 randomly
selected patients. For each standard curve, the reference DNA sample was diluted by
using a 3-fold increment per dilution to produce a seven-point standard curve, between
40 and 0.05 ng DNA in each reaction. The R2 for each standard curve was ≥ 0.98, with
acceptable standard deviation set at 0.25 (for the Ct values). If the RTL data for a tested
sample was found to be out of the acceptable range of the standard curve, the sample
was repeated.
Statistical analysis
All statistical analyses were performed using the SAS software version 9.2 (SAS
Institute, Cary, NC). The differences in the distribution of host characteristics between
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cases and controls were compared using the chi-square test for categorical variables,
and the Student’s t test for continuous variables. Wilcoxon rank-sum test was used to
evaluate the differences of RTL between cases and controls. RTL was analyzed as
categorical variable based on a cut-off point at the median, tertile, or quartile value of the
control group. The association between RTL and HCC risk was estimated using
unconditional univariate and multivariate logistic regressions to determine the
unadjusted and adjusted odds ratios (ORs), respectively, and 95% confidence intervals
(95% CIs). The multivariate analysis controlled for age, sex, smoking status, drinking
status, cirrhosis, and family history of cancer, where appropriate. The test for interaction
between demographic factors and RTL on HCC risk was conducted by including a crossproduct term into the logistic regression model. All statistical tests were two sided, and
P<0.05 was considered as the threshold of statistical significance.

RESULTS
Demographic characteristics of the study subjects
The distributions of patient characteristics were summarized in Table 1. This
study included 140 HBV-HCC cases and 280 cancer-free HBV controls that were 1:2
frequency-matched to cases on age and gender. All participants were restricted to
Korean HBV patients to control the confounding effect of ethnicity and HCC etiology. As
shown in Table 1, there was no significant differences between cases and controls on
age (mean ± standard deviation [SD], 55.3 ± 8.8 years vs. 53.7 ± 9.6 years, respectively,
P=0.099) and gender (P=0.327). No significant differences were identified between
cases and controls with regard to smoking status (P=0.096) and drinking status
(P=0.334). As expectedly, a significant higher percentage of cirrhotic patients were
identified in HCC cases (75.0%) versus controls (41.4%) (P<0.001). Additionally, there
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was a significantly higher percentage of patients with a family history of cancer among
cases (47.9%) than controls (32.9%) (P=0.003).
The distribution of RTL in cases and controls by host characteristics
As shown in Table 2, the overall serum DNA RTL was significantly longer in HCC
cases than in cancer-free HBV controls [median, 0.31 (range, 0.02-2.31) vs. median,
0.20 (range, 0.01-1.60), P=0.003]. We further conducted a stratified analysis to evaluate
the RTL distribution differences between cases and controls by host characteristics. The
differences of RTL between cases and controls remained at least borderline significant
in patients regardless of age, smoking status, and drinking status. In comparison, the
difference was only evident in males (P=0.001) but not females (P=0.757), in noncirrhotic patients (P=0.007) but not cirrhotic patients (P=0.423), and in patients without a
family history of cancer (P=0.002) but not in those with a family history of cancer
(P=0.264). Moreover, we also compared the RTL differences between the strata of each
variable in cases and controls separately, and identified a significant difference between
cirrhotic and non-cirrhotic HBV controls. The median (range) of RTL was 0.28 (0.011.60) and 0.18 (0.01-1.11) in cirrhotic and non-cirrhotic HBV controls, respectively
(P=0.004) (Table 2).
RTL and HCC risk
We estimated the association between serum DNA RTL and the risk on HCC by
univariate and multivariate logistic regression analyses, through treating RTL as a
categorical variable based on a cut off value of median, tertile or quartile distribution in
cancer-free HBV controls. As shown in Table 3, individuals with longer RTL by median
cut-off had a significantly increased risk of HCC in univariate analysis (unadjusted
OR=1.55, 95% CI, 1.02-2.33, P=0.038), but not in multivariate analysis after adjusting all
host variables including age, gender, smoking status, drinking status, cirrhosis, and
family history of cancer (adjusted OR=1.40, 95% CI 0.90-2.19, P=0.132). When patients
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were further categorized according to the tertile or quartile distribution of RTL values in
controls, we found that, using the first (shortest RTL) group as reference, there was a
significant dose-response relationship between longer RTL and increased HCC risk in
the univariate analysis (P trend=0.013 by tertile; P trend=0.017 by quartile), which was
attenuated in the multivariate analysis (P trend=0.067 by tertile; P trend=0.079 by quartile).
The OR for the second or third group in the tertile analysis was 1.15 (95% CI 0.67-1.96,
P=0.615) and 1.85 (95% CI 1.12-3.06, P=0.017), respectively in the univariate analysis,
and 1.18 (95% CI 0.67-2.08, P=0.577) and 1.64 (95% CI 0.96-2.82, P=0.072),
respectively in the multivariate analysis. Similar results were obtained in the quartile
analysis (Table 3). Because we suspected that the attenuated association between RTL
and HCC risk was due to a strong confounding from cirrhosis, we conducted another
multivariate analysis adjusting all other host variables but not cirrhosis. The result of this
analysis was similar to that of the univariate analysis: individuals with longer TRL by
median cut-off had a significantly increased HCC risk (OR=1.59; 95% CI 1.04-2.42,
P=0.031) and a significant dose-response effect was observed between longer RTL and
increased HCC risk in the tertile and quartile analysis (P trend =0.007 and 0.012,
respectively). The results of similar multivariate analysis without adjusting other host
characteristics including age, gender, smoking status, drinking status, and family history
of cancer yielded similar results to that of the multivariate analysis adjusting all the
variables (data not shown).
The association of RTL with HCC risk stratified by host characteristics
To further address the apparent attenuation of the significance of the observed
association in the multivariate analysis, we conducted a stratified analysis to evaluate
the potential modulating effect on the association between RTL and HCC risk by host
variables. Consistent with the results of Tables 2 and 3, we found a significant
association between long RTL and increased HCC risk that was observed only in non-
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cirrhotic HBV patients (adjusted OR=3.54, 95%CI 1.58-7.93, P=0.002), but not in
cirrhotic HBV patients (adjusted OR=0.95, 95% CI 0.55-1.64, P=0.860) (Table 4). A
significant association was also observed in never drinkers (adjusted OR=1.93, 95%CI
1.04-3.60, P=0.038). In addition, borderline significant associations were observed in
males (P=0.076), and patients without a family history of cancer (P=0.078) (Table 4).
Association between cirrhosis and HCC risk modulated by serum DNA RTL
Because longer RTL conferred a significantly increased risk of HCC in noncirrhotic but not in cirrhotic patients, we sought to evaluate whether the effect of cirrhosis
on HCC risk was also modulated by RTL. As shown in Table 5, as expected, cirrhosis
was significantly associated with an increased HCC risk (adjusted OR=4.11, 95% CI
2.60-6.51, P=1.48 x 10-9). This effect was much more prominent in patients with short
RTL (adjusted OR=8.04, 95% CI 3.82-16.90, P=3.89 x 10-8), compared to those with
long RTL (adjusted OR=2.35, 95% CI 1.27-4.33, P=0.006). Moreover, we observed a
statistically significant interaction effect between cirrhosis and RTL on the prediction of
the risk of HBV-HCC (P for interaction=0.013).

DISCUSSION
In the current study, we evaluated the association between RTL in circulating
cell-free serum DNA and the risk of HBV-related HCC in a clinic-based patient
population. We found that longer RTL was associated with an increased risk on HBVHCC, an effect that was much more evident in patients without cirrhosis than those with
cirrhosis. Further analysis revealed a significant interaction effect between RTL and
cirrhosis in the modulation of HCC risk in HBV patients.
The use of telomere length as a potential predictor for cancer risk and prognosis
has been extensively investigated during the past decade. The vast majority of these
studies have been focused on evaluating telomere length in tumor tissues, whereas
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increasing studies were conducted recently assessing this relationship through
measuring telomere length in PBLs using qRT-PCR [24, 25]. In HCC, many studies that
measured telomere length in tumor and surrounding normal tissue with mixed results.
The majority of these studies reported that telomere shortening was involved in
hepatocarcinogenesis, whereas there were also some studies showing that longer
telomeres contribute to increased HCC risks [11-13, 20, 26-28]. In addition to these
discrepant findings, these studies were focused mainly on the liver tissues, which reflect
more on the primary tumor characteristics than on the genetic background of the
patients. Recently, Liu et al. measured RTL in PBLs in a Chinese population, and found
that longer RTL was significantly associated with an increased risk of HBV-HCC,
comparing to both healthy controls and cancer-free controls with chronic liver diseases
such as cirrhosis or fibrosis [15]. As a surrogate specimen for individual’s genetic
background, PBL has been widely used in epidemiological studies. However, the use of
PBL as non-invasive biomarker has been limited, although they carry considerable
clinical value, especially in those prospective cohort studies with several decades’
clinical follow-up that only collected serum or plasma samples at the time of study
initiation. To the best of our knowledge, there has not been a population-based study
determining the association of serum DNA telomere length with cancer risk or clinical
outcome. In the current study, we measured the RTL in circulating cell-free serum DNA
in a Korean American HBV-infected population, and observed a significant correlation
between long RTL and increased risk of HBV-HCC. This finding is consistent with the
results of the study of Liu et al [15]. The overall median value of RTL in our study was
lower than that of Liu et al., which is possibly accounted for by the difference between
circulating cell-free DNA and PBL DNA. Circulating cell-free DNA is a heterogeneous
mixture including DNA released from various sources with broad variations in contents
and concentrations. It consists of DNA from a wide spectrum of cells such as necrotic
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and apoptotic cells, active blood cells, and circulating tumor cells in cancer patients [22],
In comparison, the DNA from PBLs is highly homogeneous and to a larger extent
reflects the constitutional genetic background of the subjects.
Cirrhosis is a major risk factor for HCC and between 60-90% of patients with
primary HCC have underlying cirrhosis [29-31]. In our study, the increased HCC risk
conferred by long serum DNA RTL was only evident in non-cirrhotic patients. This could
be due to the possibility that the strong effect of cirrhosis on HCC might have
overshadowed the association conferred by long telomere length in our study population.
Alternatively, there may be different molecular mechanisms underlying the development
of HCC with and without cirrhosis. For instance, HBV viral genome can directly integrate
into the host human genome and act as an oncogenic factor, a process that is
independent of the chronic inflammation that commonly characterizes cirrhosis [32]. In
line with this notion, recent in vitro and in vivo studies suggested that the HBx protein,
encoded by the HBV viral genome, increases both the expression of telomere reverse
transcriptase and telomerase activities, the enzyme responsible for the maintenance of
telomere length, thus prolonging the lifespan of hepatocytes and contributing to
malignant transformation [33, 34]. Partly due to these properties of HBV genome, liver
cirrhosis in patients with chronic HBV infection is only present in about 60-70% of HBVHCC cases and not a prerequisite step for tumorigenesis [35]. These lines of evidence
are consistent with our data linking telomere length and the risk of non-cirrhotic HBVHCC. However, the molecular mechanism underlying these observations still needs
further investigations.
Mixed findings have been identified from the numerous studies that have
extensively investigated the relationship between altered telomere length and cancer
risk. Wentzensen et al. conducted a meta-analysis and found that long telomere length
was associated with the increased risk of breast cancer, lung cancer, colorectal cancer,

14

and Non-Hodgkin’s lymphoma, but reduced risk of bladder cancer, esophageal cancer,
gastric cancer, head and neck cancer, ovarian cancer, and renal cell carcinoma [19]. In
HCC, our finding was consistent with the study of Liu et al., who conducted a casecontrol analysis in a Chinese population and reported that HCC patients had significantly
longer RTL measured using DNA samples of peripheral blood leukocytes, compared to
both liver disease-free normal controls and controls with chronic liver diseases such as
chronic HBV infection and liver cirrhosis [15]. However, the findings are contradictory to
several previous studies reporting that cancerous liver tissues had a shorter telomere
length compared to paired normal tissues or non-cancerous liver tissues [14, 27, 36, 37].
Several potential reasons may account for these discrepancies. Ours and Liu’s studies
were conducted in Asians whereas almost all other studies used Caucasian subjects. It
has been demonstrated there were significant racial differences in the distribution of
telomere length [38-40]. Whether these differences have an impact on the role of
telomere length in the progression of HBV-HCC remains a task of evaluation. Moreover,
our study used circulating cell-free DNA from serum samples and Liu’ study used PBLs,
whereas the majority of other studies used hepatocytes [14, 27, 36, 37]. The RTL
measurement in hepatocytes from liver tissue was more likely a reflection of the
characteristics of telomere homeostasis, rather than a simple constitutive non-invasive
biomarker of risk prediction measured from leukocytes or serum [15]. Consistent with
this notion and the results of our study, Wiemann et al. reported that in cirrhotic patients,
telomere shortening was mainly restricted to hepatocytes of cirrhotic liver tissues
whereas lymphocytes and satellite cells in areas of cirrhosis had significantly longer
telomere length [14]. Furthermore, telomere dysfunction has been reported to have dual
roles in liver carcinogenesis. Short telomere shortening appears to have a tumorinitiating effect through inducing chromosomal instability [27, 41]. In comparison, the
elongation of telomeres by the activation of telomerase has also been reported to
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contribute to tumor growth and progression [20]. Various independent studies have
demonstrated a significantly elevated activity of telomerase at the stage of severe liver
diseases such as cirrhosis and HCC [42-44], which is consistent with the findings of our
and Liu’s studies that telomere length increases along with liver disease progression.
Collectively, these lines of evidence indicate the requirement of a balanced state of
telomere length in the normal physiological liver functions, since either extremely short
or long telomeres leads to liver pathogenesis. Additional biomarker and basic studies are
needed to further explain these paradoxical findings and reveal the underlying
mechanisms.
The modulating effect of telomere length by environmental factors such as
cigarette smoking and alcohol use have been reported in HBV-HCC [15], and some
other solid tumors [45, 46]. In our study, we only observed a borderline significant
association between an increased HCC risk with long serum RTL among never drinkers
but not ever drinkers (Table 4). In addition, no significant interaction effect was identified
between RTL and smoking or drinking status (data not shown). These results may likely
be explained by the adequate matching between cases and controls on smoking and
drinking status. Moreover, due to the limitation of the retrospective clinic-based study,
we did not have detailed data of the intensities of smoking and drinking which could also
contribute to the paradox findings. Further larger prospectively designed cohort studies
are warranted to test the cumulative and interactions effects between RTL and these
environmental exposures on the risk of HCC.
A major strength of this study is the unique and highly homogenous HBV patient
population. Our study is restricted to Korean American HBV patients only, eliminating the
confounding effects of ethnicity and disease etiology. The vast majority of patients were
infected with HBV at birth or childhood, making this population an ideal resource to study
the long-term outcome of HBV infection at the population level. Strict matching criteria
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were implemented between cases and controls to minimize the potential confounding
effects from other major risk factors. To the best of our knowledge, this is the first study
to demonstrate that RTL in circulating cell-free serum DNA could potentially be used as
a simple inexpensive and non-invasive biomarker of HCC risk and the findings are highly
consistent with that obtained using PBLs [15]. This proof-of-concept finding makes
serum a valuable resource for RTL-based biomarker research, especially in prospective
longitudinal studies that have been followed-up for extended time periods but only
collected serum samples at the time of study initiation.
There are also limitations in this study. First, because of the heterogeneous
nature of circulating serum DNA, the mechanism underlying the significant associations
observed in this study remains a task for further evaluation. Second, due to the nature of
retrospective case-control design, our study also has the reverse-causation limitation
that is inherent in most case-control studies, and may not differentiate the causal
relationship between RTL alteration and HCC development. Prospective and longitudinal
studies are needed to address this issue.
In conclusion, our study reported for the first time that longer RTL in circulating
cell-free serum DNA was significantly associated with an increased risk of non-cirrhotic
HBV-HCC, a finding that warrants further retrospective and prospective validations, indepth molecular characterizations, and assessments to determine the clinical value in
the risk prediction and diagnosis of HCC.
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Table 1. Distribution of host characteristics in all cases and controls
Variable
HCC Cases ( n=140) HBV controls (n=280) P value
Age: Mean ± SD 55.3 ± 8.8
53.7 ± 9.6
0.099
Gender
Female
22(15.7)
55(19.6)
Male
118(84.3)
225(80.4)
0.327
Smoking status
Never
69(49.3)
162(57.9)
Ever
71(50.7)
118(42.1)
0.096
Drinking status
Never
67(47.9)
148(52.9)
Ever
73(52.1)
132(47.1)
0.334
Cirrhosis
No
35(25.0)
164(58.6)
< 0.001
Yes
105(75.0)
116(41.4)
Family cancer
No
73(52.1)
188(67.1)
0.003
Yes
67(47.9)
92(32.9)
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Table 2. RTL distribution by host characteristics in cases and controls
RTL: Median (Range)
Variable
HCC cases (n=140)
HBV controls (n=280)
Overall
0.31(0.02-2.31)
0.20(0.01-1.60)
Age, y
≤ 54.1
0.32(0.02-2.22)
0.22(0.02-1.15)
> 54.1
0.30(0.02-2.31)
0.18(0.01-1.60)
P value
0.998
0.414
Gender
Female
0.28(0.02-2.22)
0.26(0.01-1.60)
Male
0.32(0.02-2.31)
0.19(0.01-1.15)
P value
0.866
0.102
Smoking status
Never
0.29(0.02-2.30)
0.20(0.01-1.60)
Ever
0.32(0.02-2.31)
0.21(0.02-1.15)
P value
0.997
0.674
Drinking status
Never
0.28(0.02-2.21)
0.20(0.01-1.60)
Ever
0.34(0.02-2.31)
0.22(0.02-1.15)
P value
0.611
0.912
Cirrhosis
No
0.29(0.02-2.21)
0.18(0.01-1.11)
Yes
0.33(0.02-2.31)
0.28(0.01-1.60)
P value
0.004
0.904
Family Cancer
No
0.34(0.02-2.30)
0.20(0.01-1.60)
Yes
0.27(0.02-2.31)
0.20(0.01-1.35)
P value
0.120
0.947

P value
0.003
0.071
0.016

0.757
0.001

0.045
0.021

0.077
0.011

0.007
0.423

0.002
0.264
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Table 3. HCC risk as estimated by telomere length on HBV controls
1
2
Unadjusted
Multivariate-adjusted
Multivariate-adjusted
RTL
HCC cases
HBV controls
P Value
P Value
P Value
OR (95%CI)
OR (95%CI)
OR (95%CI)
By median
Short
55
140
1.00
1.00
1.00
1.55(1.02-2.33)
0.038
1.59(1.04-2.42)
0.031
Long
85
140
1.40(0.90-2.19)
0.132
By tertile
First tertile
35
93
1.00
1.00
1.00
Second tertile
41
95
1.15(0.67-1.96)
0.615
1.18(0.67-2.08)
0.577
1.16(0.68-2.01)
0.583
1.85(1.12-3.06)
0.017
1.99(1.18-3.32)
0.009
Third tertile
64
92
1.64(0.96-2.82)
0.072
P trend
0.013
0.007
0.067
By quartile
First quartile
26
70
1.00
1.00
1.00
Second quartile
29
70
1.12(0.60-2.08)
0.732
1.26(0.65-2.46)
0.492
1.15(0.61-2.17)
0.665
Third quartile
35
70
1.35(0.73-2.47)
0.336
1.43(0.75-2.72)
0.283
1.37(0.74-2.54)
0.316
1.92(1.08-3.43)
0.027
2.06(1.14-3.72)
0.017
Fourth quartile
50
70
1.72(0.93-3.19)
0.085
P trend
0.017
0.012
0.079
1
2
Notes: Adjusted for age, gender, smoking status, drinking status, cirrhosis and family history of cancer. Adjusted for age, gender, smoking status,
drinking status, and family history of cancer.
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Table 4. HCC risk estimated by RTL on HBV controls stratified by host characteristics
RTL (by median in
1
P value
HCC cases
HBV controls
OR (95%CI)
Variable
controls)
Age, y
≤ 53.1 Short
27
77
1.00
Long
35
72
1.21( 0.63- 2.32)
0.574
> 53.1 Short
31
75
1.00
Long
47
56
1.64( 0.88- 3.04)
0.120
Gender
Female Short
10
27
1.00
Long
12
28
0.96( 0.30- 3.07)
0.939
Male
Short
48
125
1.00
Long
70
100
1.55( 0.96- 2.52)
0.076
Smoking status
Never
Short
29
88
1.00
Long
40
74
1.49( 0.81- 2.76)
0.200
Ever
Short
29
64
1.00
Long
42
54
1.40( 0.73- 2.70)
0.312
Drinking status
Never
Short
28
84
1.00
1.93( 1.04- 3.60)
0.038
Long
39
64
Ever
Short
30
68
1.00
Long
43
64
1.06( 0.55- 2.06)
0.857
Cirrhosis
No
Short
12
101
1.00
3.54( 1.58- 7.93)
0.002
Long
23
63
Yes
Short
46
51
1.00
Long
59
65
0.95( 0.55- 1.64)
0.860
Family cancer
No
Short
28
101
1.00
Long
45
87
1.71( 0.94- 3.09)
0.078
Yes
Short
30
51
1.00
Long
37
41
1.21( 0.61- 2.38)
0.587
1

Note: Adjusted for age, gender, smoking status, drinking status, cirrhosis and family history of
cancer, where appropriate.
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Table 5. Association of cirrhosis with the risk of HBV-HCC modulated by RTL
1
P value
cirrhosis and RTL
HCC cases
HBV controls OR (95%CI)
In all patients
Non-cirrhosis
35
164
1.00
-9
4.11(2.60-6.51)
1.48 x 10
cirrhosis
105
116
In patients with short RTL
Non-cirrhosis
12
cirrhosis
46

101
51

1.00
8.04 (3.82-16.90)

3.89 x 10

In patients with long RTL
Non-cirrhosis
23
cirrhosis
59

63
65

1.00
2.35(1.27-4.33)

0.006

P interaction

-8

0.013

1

Note: Adjusted for age, gender, smoking status, drinking status, and family history of cancer.
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